Age – specific incidence rate change at breast cancer and its different histopathologic subtypes in Iran and Western countries

Ms, Hosseini; Arab, M; B, Nemati Honar; Noghabaei, Giti; Safaei, N; Ghasemi, Tahereh; Farzaneh, Farah; T, Ashraf Ganjoie

doi:10.12669/pjms.296.3788

Cited by 6 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the age group of 75-79 years had the highest incidence in 2000, followed by the age groups of 45-49, 60-64, and 50-54 .2016.17.3.1493Breast Cancer Trend in Iran from to 2009 and Prediction till 2020 with a Trend Analysis Method (Hosseini et al, 2013). In 2000, the age group 49-45 years had the highest incidence and in 2001-2005 this age group was rank second and fourth in the years 2006-2009. Other studies have reported the highest incidence of breast cancer in the age group of 45-49 years (Yip et al, 2006;Lee et al, 2007;Mousavi SM et al, 2009;Jung et al, 2013).…”

Section: Discussionmentioning

confidence: 64%

Breast Cancer Trend in Iran from 2000 to 2009 and Prediction till 2020 using a Trend Analysis Method

Zahmatkesh

Keramat²,

Alavi³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Breast cancer is the most common cancer in women worldwide with a rising incidence rate in most countries. Considering the increase in life expectancy and change in lifestyle of Iranian women, this study investigated the age-adjusted trend of breast cancer incidence during 2000-2009 and predicted its incidence to 2020. Materials and Methods: The 1997 and 2006 census results were used for the projection of female population by age through the cohort-component method over the studied years. Data from the Iranian cancer registration system were used to calculate the annual incidence rate of breast cancer. The age-adjusted incidence rate was then calculated using the WHO standard population distribution. The five-year-age-specific incidence rates were also obtained for each year and future incidence was determined using the trend analysis method. Annual percentage change (APC) was calculated through the joinpoint regression method. Results: The bias adjusted incidence rate of breast cancer increased from 16.7 per 100,000 women in 2000 to 33.6 per 100,000 women in 2009. The incidence of breast cancer had a growing trend in almost all age groups above 30 years over the studied years. In this period, the age groups of 45-65 years had the highest incidence. Investigation into the joinpoint curve showed that the curve had a steep slope with an APC of 23.4% before the first joinpoint, but became milder after this. From 2005 to 2009, the APC was calculated as 2.7%, through which the incidence of breast cancer in 2020 was predicted as 63.0 per 100,000 women. Conclusions: The age-adjusted incidence rate of breast cancer continues to increas in Iranian women. It is predicted that this trend will continue until 2020. Therefore, it seems necessary to prioritize the prevention, control and care for breast cancer in Iran.

show abstract

Section: Discussionmentioning

confidence: 64%

Breast Cancer Trend in Iran from 2000 to 2009 and Prediction till 2020 using a Trend Analysis Method

Zahmatkesh

Keramat²,

Alavi³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…With aging, the incidence of all cancers is expected to increase 16 . For women, the most important cancers are breast, colon, endometrial, ovarian and lung cancer; the latter is the leading cause of cancer mortality in many countries.…”

Section: Epidemiology Of Chronic Diseases After Menopausementioning

confidence: 99%

Prevention of diseases after menopause

et al. 2014

View full text Add to dashboard Cite

Women may expect to spend more than a third of their lives after menopause. Beginning in the sixth decade, many chronic diseases will begin to emerge, which will affect both the quality and quantity of a woman's life. Thus, the onset of menopause heralds an opportunity for prevention strategies to improve the quality of life and enhance longevity. Obesity, metabolic syndrome and diabetes, cardiovascular disease, osteoporosis and osteoarthritis, cognitive decline, dementia and depression, and cancer are the major diseases of concern. Prevention strategies at menopause have to begin with screening and careful assessment for risk factors, which should also include molecular and genetic diagnostics, as these become available. Identification of certain risks will then allow directed therapy. Evidence-based prevention for the diseases noted above include lifestyle management, cessation of smoking, curtailing excessive alcohol consumption, a healthy diet and moderate exercise, as well as mentally stimulating activities. Although the most recent publications from the follow-up studies of the Women's Health Initiative do not recommend menopause hormonal therapy as a prevention strategy, these conclusions may not be fully valid for midlife women, on the basis of the existing data. For healthy women aged 50-59 years, estrogen therapy decreases coronary heart disease and all-cause mortality; this interpretation is entirely consistent with results from other randomized, controlled trials and observational studies. Thus. as part of a comprehensive strategy to prevent chronic disease after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered as part of the armamentarium.

show abstract

“…Breast cancer affects both men and women, with a peak incidence varying between people of different regions. The incidence of breast cancer in Asia is between the age of 40 and 60 years, and in western countries it is between 60 and 70 years [ 1 ]. It is a leading cause of cancer deaths in this demographic globally.…”

Section: Introductionmentioning

confidence: 99%

“…13(0.7), 26(1), 32(1), 37(1), 39(0.8), 52(0.69), 59(1), 60(0.61), 64(0.59), 69(1), 73(1), 75(0.55), 77(1), 83(1), 85(0.45), 98(1), 102(1),104(0.84), 105(0.62), 106(0.96), 107(0.87), 110(1), 116(1) 30 Salvianolic acid A 4(0.57), 24(1), 25(0.77), 26(1), 32(1), 37(1), 43(1), 59(1), 67(0.66), 70(0.68), 73(1), 77(1), 81(0.81), 83(1), 102(0.47), 104(0.63), 110(1), 116(1)…”

unclassified

See 1 more Smart Citation

Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach

Kumar

Manandhar²,

Choudhary³

et al. 2022

Mol Divers

View full text Add to dashboard Cite

Breast cancer is a common form of cancer that affects both men and women. One of the most common types of genomic flaws in cancer is the aberrations in the PI3K/AKT/mTOR pathway. The benefit of dual targeting PI3K as well as mTOR is that the kinase-positive feedback loops are more effectively inhibited. Therefore, in the current study, structure-based models like molecular docking, MM-GBSA, Qikprop, induced fit docking, simulated molecular dynamics (MD), and thermal MM-GBSA were used to identify the phytochemicals from the zinc 15 database, which may inhibit PI3K and mTOR. After docking the phytochemicals with PI3K (PDB 4FA6), ten ligands based on the docking score were selected, among which salvianolic acid C had the highest docking score. Hence, salvianolic acid A was also docked. All the ligands taken showed a binding energy of greater than − 30 kcal/mol. The predicted ADME showed that the ligands have druggable properties. By performing MD of the top five ligands and salvianolic acid A, it was found that ZINC000059728582, ZINC000257545754, ZINC000253532301, and salvianolic acid A form a stable complex with PI3K protein, among which ZINC000014690026 showed interaction with Val 882 for more than 89% of the time. Salvianolic acid A is already proven to suppress tumor growth in acute myeloid leukemia by inhibiting PI3K/AKT pathway, but the exact protein target is unknown. Therefore, the present study identifies new molecules and provides evidence for salvianolic acid A for dual inhibition. Further experiments must be performed both in vitro and in vivo to support the predictions of these computational tools. Graphical abstract

show abstract

Age – specific incidence rate change at breast cancer and its different histopathologic subtypes in Iran and Western countries

Cited by 6 publications

References 10 publications

Breast Cancer Trend in Iran from 2000 to 2009 and Prediction till 2020 using a Trend Analysis Method

Breast Cancer Trend in Iran from 2000 to 2009 and Prediction till 2020 using a Trend Analysis Method

Prevention of diseases after menopause

Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach

Contact Info

Product

Resources

About